What Vertex Pharmaceuticals’ Valuation Trend Indicates

In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.